Jan Børge Jakobsen, managing director of Bayer Norway, shares how he came to lead Bayer’s Norwegian affiliate after 30 years within the Norwegian pharma industry; Norway’s innovation capabilities in radiopharmaceuticals; and his excitement surrounding Bayer’s portfolio and upcoming product launches in Norway.
Through the acquisition and integration of Algeta, Bayer’s Norwegian operations have become one of the company’s global R&D and innovation hubs for radiopharmaceuticals. Radiopharmaceuticals in Norway, and especially the Oslo area, as such has developed into an international centre of excellence
